coronary heart disease
Conditions
Interventions
Experimental Group:Adopt an individualized cardiac rehabilitation strategy that combines disease and syndrome based on a remote health management cloud platform.
Control group:Adopt a center-based disease combined with cardiac rehabilitation strategy.
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) The PCI operation was successfully performed; (2) Age >=18 years old; (3) Possess at least one high-risk anatomical or clinical feature: Anatomical features: left main trunk lesion, bifurcation lesion, opening lesion, chronic complete occlusion lesion, multi-vessel lesion (>=2 vessels stent implantation), restenosis lesion, diffuse long lesion (lesion length >=30mm or stent length >=32mm) or bypass graft; Clinical features: Diabetes, renal insufficiency/failure (GFR50% or more; (5) Voluntarily accept all the examinations and follow-up evaluations required by the research protocol; (6) No cognitive dysfunction and proficient in using Internet apps; (7) The subject (or legal guardian) understands the research requirements and treatment procedures, and signs a written informed consent form before performing the examinations or operations stipulated in the protocol.
Exclusion criteria
Exclusion criteria: (1) Still having absolute/relative contraindications for CPET after PCI; (2) The subjects cannot tolerate the secondary prevention drug treatment for coronary heart disease; (3) Combined with other organ failure, such as severe liver function impairment (AST or ALT elevation more than three times the upper limit of normal value), combined with severe congestive heart failure (cardiac function > grade III), etc. Suffering from serious diseases with an expected lifespan of less than 12 months, such as malignant tumors, advanced stages of other diseases, etc. (4) Pregnant women and those planning to become pregnant; (5) Patients with cognitive impairment, severe hearing or vision damage who are unable to complete pre-grouping communication and refuse re-examination; (6) Currently participating in another clinical trial of a drug or device that has not yet reached the primary endpoint, or planning to participate in another clinical trial of a drug or device within 12 months after the operation; (7) Failure to obtain informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of PVO2 in the two groups of patients at 3 and 12 months of follow-up.; | — |
Secondary
| Measure | Time frame |
|---|---|
| the major adverse cardiovacular events: including recurrent angina pectoris, acute myocardial infarction, unplanned revascularization, severe arrhythmia, heart failure, and cardiogenic death;Tongue appearance: tongue color, tongue body, sublingual veins, coating on the tongue, coating color;Morisky Scale;Seattle Angina Questionnaire;SF-36 Scale;Anxiety and depression score;Quality-adjusted life year;Incremental cost-effectiveness ratio; | — |
Countries
China
Contacts
Public ContactGe Changjiang
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed